Mesenchymal stem cells in the treatment of spinal cord injuries: A review.
Mesenchymal stem cells in the treatment of spinal cord injuries: A review.
复制标题
DOI：
10.4252/wjsc.v6.i2.120
复制
发表时间：
2014-04-26
影响因子：
4.1
通讯作者：
Dinh, Dzung H
中科院分区：
文献类型：
--
作者：
Dasari, Venkata Ramesh;Veeravalli, Krishna Kumar;Dinh, Dzung H
随着基础研究技术的不断进步，继发性延迟性脊髓损伤（SCI）的复杂机制不断被快速揭示。然而，尽管我们对脊髓最初损伤后发生的分子变化有了更深入的了解，但瘫痪的治疗仍然难以捉摸。目前对脊髓损伤的治疗仅限于早期给药高剂量类固醇，以减轻脊髓损伤后发生的脊髓水肿的有害影响，并减少继发性延迟性脊髓损伤的级联。最近基于证据的临床研究对类固醇治疗脊髓损伤的临床益处提出了质疑，而对干细胞治疗的强烈关注已经产生了一些令人鼓舞的结果。来自各种来源的间充质干细胞（MSCs）具有新颖和有前途的策略，正在被开发用于改善脊髓损伤后的功能。在这篇综述中，我们简要地讨论了脊髓损伤的病理生理和特点，以及可用于脊髓损伤治疗的间充质干细胞的潜在来源。我们将讨论MSCs在研究中的应用进展，重点讨论MSCs的神经保护作用。最后，我们将讨论涉及干细胞治疗脊髓损伤的临床前和临床试验的结果。
With technological advances in basic research, the intricate mechanism of secondary delayed spinal cord injury (SCI) continues to unravel at a rapid pace. However, despite our deeper understanding of the molecular changes occurring after initial insult to the spinal cord, the cure for paralysis remains elusive. Current treatment of SCI is limited to early administration of high dose steroids to mitigate the harmful effect of cord edema that occurs after SCI and to reduce the cascade of secondary delayed SCI. Recent evident-based clinical studies have cast doubt on the clinical benefit of steroids in SCI and intense focus on stem cell-based therapy has yielded some encouraging results. An array of mesenchymal stem cells (MSCs) from various sources with novel and promising strategies are being developed to improve function after SCI. In this review, we briefly discuss the pathophysiology of spinal cord injuries and characteristics and the potential sources of MSCs that can be used in the treatment of SCI. We will discuss the progress of MSCs application in research, focusing on the neuroprotective properties of MSCs. Finally, we will discuss the results from preclinical and clinical trials involving stem cell-based therapy in SCI.